In this episode, David Flores sits down with Cannara CFO Nicholas Sosiak, to discuss the Company's future goals and to spotlight what differentiates Cannara from other companies in the cannabis space.
Similar Posts
Breaking News: MindMed launches LSD Microdosing Trial Treating ADHD (Plus MNMD Stock Discussion)
MindMed (Nasdaq:MNMD, NEO:MMED) has launched recruitment for their phase 2a clinical trial, testing using LSD microdoses to treat Adult ADHD!
MindMed’s stock has been down a lot recently, which has people asking “should I sell MindMed”, or “Is MindMed stock a good investment?”, or “why is MindMed stock down?”.
A lot of this drop has to do with a lack of news, not bad news. Now, at long last we finally have some good news! I have been looking forward to this trial starting for over a year now!
This LSD microdosing study is part of Project Flow, MindMed’s LSD microdosing division.
Microdosing LSD, anecdotally, has been shown to: increase focus; decrease anxiety; increase creativity; and improve mood. As improving focus and decreasing anxiety are two issues individuals with ADHD often need help with, it is possible that this may be a better medication than stimulants like Adderall.
The 52 person, placebo controlled study will give 20 micrograms of LSD to Adult ADHD sufferers twice a week for 6 weeks. Six weeks after treatment, the patients symptoms will be compared to where they were before the trial, and compared against the placebo group.
If they do show significant improvement, it will be the first scientific evidence that LSD microdoses can help treat adult ADHD.
Not only would this help tens of millions of people, it would also be lucrative for MindMed, as in the USA alone, the ADHD treatment market is valued at $12.9 billion annually.
Is LSD microdosing good for you? Can LSD Microdosing improve your mental health and Creativity? MindMed aims to find out!
References:
Press Release
https://www.prnewswire.com/news-releases/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-301447252.html
MindMed Investor’s Deck
https://mindmed.co/wp-content/uploads/2021/12/MindMed-Presentation-December-2021.pdf
New CEO
https://www.newswire.ca/news-releases/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director-879570624.html
Microdosing study 1
https://pubmed.ncbi.nlm.nih.gov/34795334/
Microdosing study 2
https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
@Psychedelic Spotlight
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #Microdosing #ADHD
Five Telling Takeways from Benzinga Psychedelics Capital Conference
Five Telling Takeways from Benzinga Psychedelics Capital Conference Join our…
The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor
The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor
Join the Psychedelic Investor and the CEOs of MindMed (Rob Barrow) and Cybin (Doug Drysdale), and the Executive Chairman of Field Trip (Ronan Levy) as they discuss the future of psychedelic medicines.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
If you are interested in investing in psychedelic stocks, then this is the even for you. Full of knowledge and unique information, this CEO discussion is a must.
Learn about the companies behind MindMed’s stock (Nasdaq: MNMD, NEO: MMED), Cybin’s stock (NYSE: CYBN, NEO: CYBN) and Field Trip Health’s stock (Nasdaq: FTRP, TSX: FTRP).
Presented by PsychedelicSpotlight.com, this conversation is as great a starting place as any to learn about psychedelic stocks
#Psychedelics #MindMed #Investing
Is MindMed the NEXT Tesla? (MindMed Bull Thesis)
Is MindMed (MMED / MMEDF) the next Tesla (TSLA)? It could be. In this video we give the bull case scenario for MindMed, and give a general company overview.
MindMed (MMED) is our favorite psychedelic stock by far, with trials using LSD to treat anxiety and ADHD, as well as their proprietary 18-MC compound to treat addiction.
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
► Music Credit: LAKEY INSPIRED
Track Name: “Blue Boi”
Music By: LAKEY INSPIRED @ https://soundcloud.com/lakeyinspired
Original upload HERE – https://www.youtube.com/watch?v=wAukv…
Official “LAKEY INSPIRED” YouTube Channel HERE – https://www.youtube.com/channel/UCOmy…
License for commercial use: Creative Commons Attribution 3.0 Unported “Share Alike” (CC BY-SA 3.0) License.
Full License HERE – https://creativecommons.org/licenses/…
Music promoted by NCM https://goo.gl/fh3rEJ
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Links from studies and websites :
https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm?fbclid=IwAR3_UBSk2yv4lwOld0su1YpnJHsjPA4x5XK-X2pO5LMz1AeXiojkswcDV8Y#:~:text=Anestimated69029peopledied,wereduetoheroin
https://www.hhs.gov/opioids/about-the-epidemic/index.html?fbclid=IwAR0df0UXoVhfWf03RQNkP5OMInM5Nyxz6j68V5GXr5lv0lDUuRL_R-UL4ZA
https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction?fbclid=IwAR31PQiu49359xjhzD4sTgcicRQLGh-l95y2DuFihHPdql87eHTDnYsTELw
https://preprod.drugfree.org/article/relapse-overdose/?fbclid=IwAR1YSZEIUDCiYDeBIYCk1WhEA_NJCrjyyz56zteyrbGKhDYQtsu2X1fDVOM
https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery?fbclid=IwAR2_c4gVhURANeU5pCc0k97Ba4ML-kYZIGOZvGfqpHmo8o4jdxZp0SEHyQQ
https://maps.org/research-archive/presentations/Brown_GITA_Vancouver_Oct2012_iboga_comm_rev.pdf
https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218?fbclid=IwAR0OBK0eFJ64-v7gu1yE1TnyUIK1XhSDJvd_XLxhZaRtC4bWF8MfD0ine3M
https://www.healio.com/news/primary-care/20191205/ibogaine-treatment-for-opioid-use-disorder-what-you-need-to-know?fbclid=IwAR39o1sonUGLHsMGwH3pzbm3aAkU98P15CFNYaQX0r3VNQtJdSy3pazvRJM#
https://mindmed.co/psychedelic-inspired/?fbclid=IwAR1EK84fYX4WrObq45LkQfkZiW3ZtUYNsVZ4Y9q_wMHqas7y8IwoJmFyTBs#scroll_section-1
https://www.globenewswire.com/news-release/2020/02/20/1988216/0/en/Drug-Addiction-Treatment-Market-To-Reach-USD-31-17-Billion-By-2027-Reports-And-Data.html?fbclid=IwAR2ZeDBuW69x1DkczkxVRmadUBTpwu1Dilur64LkqBISH1Dqu8FC3EgFzmU
https://adaa.org/about-adaa/press-room/facts-statistics?fbclid=IwAR2YlG6rTd0jdUP3XIkm0t-_-QRYDyWDlVGh_sF6CZkayVEyGUZZpGcplwE#:~:text=Anxietydisordersarethemost,ofthosesufferingreceivetreatment
https://adaa.org/finding-help/treatment/medication?fbclid=IwAR10tRsqwdRMx-PqpKA9yx5BPGvNcVJRugkw3L6tq7DrDIO4gVdNwb6BGJ4
https://www.newswire.ca/news-releases/mindmed-receives-approval-of-protocol-design-to-evaluate-microdoses-of-lsd-for-adult-adhd-in-phase-2a-clinical-trial-from-swiss-and-dutch-health-authorities-897700369.html?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng
https://maps.org/research-archive/lsd/Gasser-2014-JMND-4March14.pdf
https://www.smartpatients.com/trials/NCT03153579?fbclid=IwAR0df0UXoVhfWf03RQNkP5OMInM5Nyxz6j68V5GXr5lv0lDUuRL_R-UL4ZA
https://www.marketwatch.com/press-release/global-anxiety-disorders-and-depression-treatment-market-2020-research-report-with-consumption-revenue-opportunities-market-share-and-growth-rate-covid-19-impact-and-forecast-to-2026-absolute-reports-2020-11-06?fbclid=IwAR1jEtR6h9mTPla8OzW5RiIW2ecf_HnrT7of42bU4mO5dsfpxxuCAFv-7bE
https://www.additudemag.com/statistics-of-adhd/?fbclid=IwAR1mQaSVujUayYXwzCQRryiCZzM4gckjKAbg5O9H5BwCJIUbrXypOlgU4qM#:~:text=About6.1millionchildrenin,ControlandPrevention(CDC)
https://www.additudemag.com/adhd-medication-for-adults-and-children/?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng
https://www.floridarehab.com/drugs/meth/related/meth-vs-adderall/?fbclid=IwAR0WbOJtUIMcW4sPsQ7TUR-ulrPC9rwa1b2_KxHw_lFJBk_ygesCtsQJqDs
https://www.drugwatch.com/adderall/side-effects/?fbclid=IwAR3_UBSk2yv4lwOld0su1YpnJHsjPA4x5XK-X2pO5LMz1AeXiojkswcDV8Y
https://drug-dev.com/adhd-treatment-market-value-to-reach-9-9-billion/?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng
https://mindmed.co/team/
#MindMed #MMED #Mindmedstock #Tesla #TSLA #PsychedelicStocks #ThePsychedelicInvestor
Activate Altered States Faster with Vibroacoustics – with Craig Goldberg
This episode dives into inHarmony’s meditation cushion and how involuntary elevated altered states of consciousness are achieved through the power of vibrations!
MindMed Near Term CATALYSTS & Nasdaq Debrief [MMED / MNMD]
So what happened with MindMed (MMED / MNMD) on the day on the NASDAQ uplisting? As we all know, MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.
Ever since, we all speculated on what will happen to the MindMed stock on April 27 and what will be it’s closing price? On April 26th, the stock price rose to near all time highs and a lot of retail investors thought that on the 27th, the run will continue. MindMed’s move to the Nasdaq was to increase the visibility of its stock in hopes of reaching out to a new group of retail and institutional investors.
Unfortunately, the plan didn’t go so well. While MindMed opened at the previous all time high, the stock dropped throughout the day. MindMed, (MNMD) closed today after its first day on the Nasdaq at: $4.02, down 16%,
most probably due to investors who took some profits, which was one of the scenarios in our previous video on MindMed Nasdaq Uplisting price predictions.
So in this video, I’ll share my thoughts on today’s MMED / MNMD stock events and then discuss the near time future catalysts for MindMed.
Timestamps:
0:00 – Intro
1:27 – Thoughts on MindMed (MNMD) first trading day on NASDAQ
6:05 – MindMed catalyst #1 – Atai’s IPO
7:37 – PSIL ETF coming soon
9:58 – Phase 2a results for MindMed’s Project LUCY
11:38 – Project LUCY starting Phase2b in Q4 this year
12:26 – Completion of Phase 1 Trial for Project Layla (18-MC)
13:08 – Completion of Phase 1 LSD Neutralizer Study
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Links to Clinical trials :
https://clinicaltrials.gov/ct2/results?cond=&term=LSD&cntry=&state=&city=&dist=
https://clinicaltrials.gov/ct2/show/NCT03153579?term=LSD&draw=2&rank=5&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY
https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD&draw=2&rank=6&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY
https://mindmed.co/wp-content/uploads/2021/04/MindMed-Corporate-Presentation-4.27.2021.pdf
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock